Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors

Blood Adv. 2020 Nov 10;4(21):5336-5342. doi: 10.1182/bloodadvances.2020001528.

Abstract

  1. IDH1/2-inhibitor–based combinations conferred significant clinical responses in patients with IDH1/2-mutated post–MPN AML.

  2. Complete remission was achieved in 3/7 patients (1 attaining MRD–) with new IDH1/2-mutated post–MPN AML treated with IDH1/2-i combinations.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Myeloproliferative Disorders* / drug therapy
  • Myeloproliferative Disorders* / genetics

Substances

  • Isocitrate Dehydrogenase
  • IDH1 protein, human